SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 3.62 |
| Enterprise Value ($M) | 5.10 |
| Book Value ($M) | -6.79 |
| Book Value / Share | -0.94 |
| Price / Book | -0.53 |
| NCAV ($M) | -6.79 |
| NCAV / Share | -0.94 |
| Price / NCAV | -0.53 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | n/a |
| Return on Assets (ROA) | -11.68 |
| Return on Equity (ROE) | n/a |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.03 |
| Current Ratio | 0.03 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 0.14 |
| Assets | 0.14 |
| Liabilities | 6.93 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -0.88 |
| Net Income | -0.92 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -0.24 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.20 |
(click for more detail) |
|
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Similar Companies | |
|---|---|
| CMVLF – Cellectis S.A. | CNBX – CNBX Pharmaceuticals Inc. |
| CPMD – CannaPharmaRX, Inc. | CSBTF – Kuros Biosciences AG |
| CUBT – Curative Biotechnology, Inc. |
Financial data and stock pages provided by
Fintel.io